190 related articles for article (PubMed ID: 38173208)
1. Identification of Novel EGFR Inhibitors for the Targeted Therapy of Colorectal Cancer Using Pharmacophore Modelling, Docking, Molecular Dynamic Simulation and Biological Activity Prediction.
Krishnan K A; Valavi SG; Joy A
Anticancer Agents Med Chem; 2024; 24(4):263-279. PubMed ID: 38173208
[TBL] [Abstract][Full Text] [Related]
2. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
[TBL] [Abstract][Full Text] [Related]
3. Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches.
Jethwa M; Gangopadhyay A; Saha A
J Biomol Struct Dyn; 2023 Mar; 41(5):1681-1689. PubMed ID: 35014597
[TBL] [Abstract][Full Text] [Related]
4. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
[TBL] [Abstract][Full Text] [Related]
5. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.
Ashiru MA; Ogunyemi SO; Temionu OR; Ajibare AC; Cicero-Mfon NC; Ihekuna OA; Jagun MO; Abdulmumin L; Adisa QK; Asibor YE; Okorie CJ; Lawal MO; Babalola MO; Abdulrasaq IT; Salau LB; Olatunji IO; Bankole MA; Daud AB; Adeyemi AO
J Mol Model; 2023 Apr; 29(5):128. PubMed ID: 37016200
[TBL] [Abstract][Full Text] [Related]
6.
Imana SN; Ningsih EG; Tambunan USF
Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
[TBL] [Abstract][Full Text] [Related]
7. In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents.
Debnath S; Kanakaraju M; Islam M; Yeeravalli R; Sen D; Das A
Comput Biol Chem; 2019 Dec; 83():107156. PubMed ID: 31710991
[TBL] [Abstract][Full Text] [Related]
8. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
Sangande F; Julianti E; Tjahjono DH
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical cancer.
Mohan A; Krishnamoorthy S; Sabanayagam R; Schwenk G; Feng E; Ji HF; Muthusami S
Eur J Pharmacol; 2023 Oct; 957():175961. PubMed ID: 37549730
[TBL] [Abstract][Full Text] [Related]
10. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFR
Saini R; Kumari S; Bhatnagar A; Singh A; Mishra A
Sci Rep; 2023 Jun; 13(1):8885. PubMed ID: 37264083
[TBL] [Abstract][Full Text] [Related]
12. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore, 3D-QSAR Models and Dynamic Simulation of 1,4-Benzothiazines for Colorectal Cancer Treatment.
Rai A; Raj V; Aboumanei MH; Singh AK; Keshari AK; Verma SP; Saha S
Comb Chem High Throughput Screen; 2017; 20(8):658-674. PubMed ID: 28486913
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
Panicker PS; Melge AR; Biswas L; Keechilat P; Mohan CG
Chem Biol Drug Des; 2017 Oct; 90(4):629-636. PubMed ID: 28303669
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
16. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
Bhojwani HR; Joshi UJ
Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
Rathi E; Kumar A; Kini SG
J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
20. An In Silico Investigation of Potential EGFR Inhibitors for the Clinical Treatment of Colorectal Cancer.
Majhi M; Ali MA; Limaye A; Sinha K; Bairagi P; Chouksey M; Shukla R; Kanwar N; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2018; 18(27):2355-2366. PubMed ID: 30499396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]